JP2020198791A - Sleep-improving composition, and food, drug and feed containing the composition - Google Patents

Sleep-improving composition, and food, drug and feed containing the composition Download PDF

Info

Publication number
JP2020198791A
JP2020198791A JP2019106129A JP2019106129A JP2020198791A JP 2020198791 A JP2020198791 A JP 2020198791A JP 2019106129 A JP2019106129 A JP 2019106129A JP 2019106129 A JP2019106129 A JP 2019106129A JP 2020198791 A JP2020198791 A JP 2020198791A
Authority
JP
Japan
Prior art keywords
sleep
improving
composition
whey protein
protein hydrolyzate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019106129A
Other languages
Japanese (ja)
Other versions
JP7428480B2 (en
Inventor
弘樹 村上
Hiroki Murakami
弘樹 村上
太郎 神
Taro Jin
太郎 神
利信 新井
Toshinobu Arai
利信 新井
祥雄 塚田
Yoshio Tsukada
祥雄 塚田
如一 森田
Yukikazu Morita
如一 森田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Snow Brand Milk Products Co Ltd
Original Assignee
Snow Brand Milk Products Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Snow Brand Milk Products Co Ltd filed Critical Snow Brand Milk Products Co Ltd
Priority to JP2019106129A priority Critical patent/JP7428480B2/en
Publication of JP2020198791A publication Critical patent/JP2020198791A/en
Application granted granted Critical
Publication of JP7428480B2 publication Critical patent/JP7428480B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P60/00Technologies relating to agriculture, livestock or agroalimentary industries
    • Y02P60/80Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
    • Y02P60/87Re-use of by-products of food processing for fodder production

Landscapes

  • Fodder In General (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

To provide a sleep-improving composition capable of increasing non-REM sleep time and excellent in stability and safety, and food, food compositions, drug, drug compositions, and feed containing the sleep-improving composition.SOLUTION: The sleep-improving composition includes whey protein hydrolysate as an active ingredient; in particular, the whey protein hydrolysate is characterized in having a molecular weight distribution of a width of 10 kDa or less and a main peak molecular weight of 200 Da to 3 kDa, APL (average peptide length) of 2 to 8, a free amino acid content of 20% or less, and an antigenicity of 1/10,000 or less of that of β-lactoglobulin. There are also provided sleep-improving food, sleep-improving food compositions, sleep-improving drug, sleep-improving drug compositions, or sleep-improving feed containing the sleep-improving composition.SELECTED DRAWING: Figure 1

Description

本発明は、睡眠を改善させ、安定性及び安全性に優れた睡眠改善用組成物に関する。また、本発明は、該睡眠改善用組成物を含有する、食品、食品組成物、医薬品、医薬組成物、及び飼料に関する。 The present invention relates to a sleep-improving composition that improves sleep and is excellent in stability and safety. The present invention also relates to foods, food compositions, pharmaceuticals, pharmaceutical compositions, and feeds containing the sleep-improving composition.

近年、ライフスタイルの変化により、生活リズムが乱れ、不眠などの睡眠障害の罹患率が上昇している。厚生労働省の調査によると5人に1人は何らかの睡眠に関する悩みを抱えている(非特許文献1)。睡眠障害は、眠気などによる労働生産性の低下だけでなく、認知症やうつ病などの精神疾患、肥満や糖尿病などの生活習慣病と密接に関連することが明らかとなった。この睡眠不足による経済損失は約3.5兆円になると試算されている(非特許文献2)。 In recent years, changes in lifestyle have disturbed the rhythm of life, and the prevalence of sleep disorders such as insomnia has increased. According to a survey by the Ministry of Health, Labor and Welfare, one in five people has some sort of sleep problem (Non-Patent Document 1). It has been clarified that sleep disorders are closely related not only to the decrease in labor productivity due to drowsiness, but also to mental illnesses such as dementia and depression, and lifestyle-related diseases such as obesity and diabetes. The economic loss due to this lack of sleep is estimated to be about 3.5 trillion yen (Non-Patent Document 2).

不眠などの睡眠障害を持つ人に対しては、医薬品である睡眠薬の使用が考えられる。睡眠薬としては、バルビツール酸系睡眠薬やベンゾジアゼピン系睡眠薬、非ベンゾジアゼピン系睡眠薬が主として用いられている。しかしながら、バルビツール酸系睡眠薬は依存性などの副作用が強く、ベンゾジアゼピン系睡眠薬による睡眠は、ベンゾジアゼピン速波と呼ばれる異常な周波数領域を示す睡眠を誘発するため、生理的で良質な睡眠を導かないことが知られている。また、ベンゾジアゼピン系及び非ベンゾジアゼピン系の睡眠薬は、いずれも、ふらつき、頭痛、めまい等の副作用や入眠までの出来事や中途覚醒時の出来事を覚えていないなどの症状が現れる場合があることが知られている。 For people with sleep disorders such as insomnia, the use of sleeping pills, which are medicines, may be considered. As the hypnotic, barbituric acid hypnotics, benzodiazepine hypnotics, and non-benzodiazepine hypnotics are mainly used. However, barbituric acid hypnotics have strong side effects such as dependence, and sleep with benzodiazepine hypnotics induces sleep showing an abnormal frequency range called benzodiazepine hypnotics, so it should not lead to physiological and good quality sleep. It has been known. In addition, it is known that both benzodiazepine and non-benzodiazepine hypnotics may cause side effects such as light-headedness, headache, dizziness, and symptoms such as not remembering the events leading up to falling asleep or the events during awakening. ing.

このことから、医薬品に代わり日常的に摂取することができ、生理的な睡眠を誘発することができる素材の開発が盛んに実施されており、天然成分や食品成分などから様々なものが提案されている。例えば、アミノ酸であるグリシンによる熟眠障害改善剤(特許文献1)や、テアニンによる睡眠促進組成物(特許文献2)がある。 For this reason, the development of materials that can be taken on a daily basis instead of pharmaceuticals and that can induce physiological sleep is being actively carried out, and various natural ingredients and food ingredients have been proposed. ing. For example, there are a sleep disorder improving agent using glycine, which is an amino acid (Patent Document 1), and a sleep promoting composition using theanine (Patent Document 2).

牛乳や乳製品は古来より食されており、入眠前に加温した牛乳を摂取することで、寝つきが良くなるなど、睡眠が改善されるといわれている。実際にホエイに含まれるαラクトアルブミンによる睡眠改善効果が報告されている(非特許文献3)。また、牛乳カゼイン由来のペプチドによる不安症、睡眠障害及びてんかんを治療できるとする旨の特許が報告されている(特許文献3)。 Milk and dairy products have been eaten since ancient times, and it is said that ingesting warmed milk before falling asleep improves sleep, such as improving sleep. It has been reported that α-lactalbumin actually contained in whey has a sleep improving effect (Non-Patent Document 3). In addition, a patent has been reported that can treat anxiety, sleep disorders, and epilepsy caused by peptides derived from milk casein (Patent Document 3).

しかしながら、前出のαラクトアルブミンの摂取により睡眠改善効果を得るためには、1日あたり40gの摂取が必要であり、日常的に摂取するのは困難である。また、牛乳カゼイン由来のペプチドに関する特許では、不安様行動について動物の行動を目視やビデオ撮影によって評価しているのみであり、該ペプチドが実際に睡眠障害を治療できるかは明らかではなく、実証されたこのペプチドの効果は、抗不安作用に限られる。 However, in order to obtain the sleep improving effect by taking the above-mentioned α-lactalbumin, it is necessary to take 40 g per day, which is difficult to take on a daily basis. In addition, the patent on milk casein-derived peptides only evaluates animal behavior for anxiety-like behavior by visual inspection or videography, and it is not clear or demonstrated whether the peptide can actually treat sleep disorders. The effects of this peptide are limited to anxiety.

特開2013-121961号公報Japanese Unexamined Patent Publication No. 2013-121961 国際公開WO01/074352号公報International Publication WO 01/074352 特表2011-524163号公報Special Table 2011-524163

平成26年度国民健康・栄養調査2014 National Health and Nutrition Survey 内山 真, 日本精神科病院協会雑誌 31(11), 1163-1169, 2012-11Makoto Uchiyama, Japan Psychiatric Hospital Association Magazine 31 (11), 1163-1169, 2012-11 Markus, C. R. et. al.: Am. J. Clin. Nutr.,81,1026-1033,2005Markus, C.R. et. Al .: Am. J. Clin. Nutr., 81,1026-1033,2005

本発明は、睡眠を改善させ、安定性及び安全性に優れた睡眠改善用組成物を提供することを課題とする。また、本発明は、該睡眠改善用組成物を含有する食品、食品組成物、医薬品、医薬組成物、及び飼料を提供することを課題とする。 An object of the present invention is to provide a sleep improving composition which improves sleep and is excellent in stability and safety. Another object of the present invention is to provide a food, a food composition, a pharmaceutical product, a pharmaceutical composition, and a feed containing the sleep improving composition.

本発明者らは、上記の課題を解決するため鋭意検討を進めたところ、ホエイタンパク質加水分解物が睡眠を改善させ、その効果は加水分解前のホエイタンパク質よりも有意に強いことを見出した。
すなわち本発明は、以下の様態を含むものである。
(1)ホエイタンパク質加水分解物を有効成分とする睡眠改善用組成物。
(2)前記睡眠改善用組成物が、ノンレム睡眠時間増加用組成物、睡眠時間増加用組成物、及び睡眠導入促進用組成物からなる群より選択される1つ以上であることを特徴とする、(1)に記載の睡眠改善用組成物。
(3)前記ホエイタンパク質加水分解物の分解率が25%以上であることを特徴とする(1)又は(2)のいずれかに記載の睡眠改善用組成物。
(4)前記ホエイタンパク質加水分解物が、以下の特徴を有するものである(1)から(3)のいずれかに記載の睡眠改善用組成物。
(A)分子量分布は10kDa以下、メインピーク200Da〜3kDaである。
(B)APL(平均ペプチド鎖長)は2〜8である。
(C)遊離アミノ酸含量が20%以下である。
(D)抗原性がβ-ラクトグロブリンの抗原性の1/10,000以下である。
(5)前記ホエイタンパク質加水分解物が、ホエイタンパク質をpH6〜10、50〜70℃において耐熱性のタンパク質加水分解酵素を用いて熱変性させながら酵素分解し、加熱して酵素を失活させて得られるものであることを特徴とする(1)から(4)のいずれかに記載の睡眠改善用組成物。
(6)前記ホエイタンパク質加水分解物が、ホエイタンパク質をpH6〜10、20〜55℃においてタンパク質加水分解酵素を用いて酵素分解し、これを50〜70℃に昇温させ、pH6〜10、50〜70℃において耐熱性のタンパク質加水分解酵素を用いて未分解のホエイタンパク質を熱変性させながら酵素分解し、加熱して酵素を失活させて得られるものであることを特徴とする(1)から(4)のいずれかに記載の睡眠改善用組成物。
(7)(1)から(6)のいずれかに記載の睡眠改善用組成物を含むことを特徴とする睡眠改善用食品、睡眠改善用食品組成物、睡眠改善用医薬品、睡眠改善用医薬品組成物、又は睡眠改善用飼料。
As a result of diligent studies to solve the above problems, the present inventors have found that whey protein hydrolyzate improves sleep, and its effect is significantly stronger than that of whey protein before hydrolysis.
That is, the present invention includes the following aspects.
(1) A composition for improving sleep containing a whey protein hydrolyzate as an active ingredient.
(2) The sleep improving composition is one or more selected from the group consisting of a non-REM sleep time increasing composition, a sleep time increasing composition, and a sleep induction promoting composition. , (1). The composition for improving sleep.
(3) The sleep improving composition according to any one of (1) and (2), wherein the decomposition rate of the whey protein hydrolyzate is 25% or more.
(4) The sleep-improving composition according to any one of (1) to (3), wherein the whey protein hydrolyzate has the following characteristics.
(A) The molecular weight distribution is 10 kDa or less, and the main peak is 200 Da to 3 kDa.
(B) APL (mean peptide chain length) is 2-8.
(C) The free amino acid content is 20% or less.
(D) The antigenicity is 1 / 10,000 or less of the antigenicity of β-lactoglobulin.
(5) The whey protein hydrolyzate enzymatically decomposes whey protein at pH 6 to 10 and 50 to 70 ° C. while heat-denaturing it with a heat-resistant protein hydrolase, and heats it to inactivate the enzyme. The composition for improving sleep according to any one of (1) to (4), which is obtained.
(6) The whey protein hydrolyzate enzymatically decomposes whey protein at pH 6 to 10, 20 to 55 ° C. using a protein hydrolyzate enzyme, raises the temperature to 50 to 70 ° C., and pH 6 to 10, 50. It is characterized in that it is obtained by enzymatically decomposing undegraded whey protein using a heat-resistant protein hydrolyzate at ~ 70 ° C while heat-denaturing it, and inactivating the enzyme by heating (1). To the composition for improving sleep according to any one of (4).
(7) A sleep-improving food, a sleep-improving food composition, a sleep-improving drug, a sleep-improving drug composition, which comprises the sleep-improving composition according to any one of (1) to (6). Things or feed for improving sleep.

本発明は、新規な睡眠改善用組成物を提供するものであり、本願でいう睡眠改善とは、ノンレム睡眠時間の増加、1日あたりの睡眠時間の増加、または入眠潜時の短縮の1つ以上を指している。 The present invention provides a novel composition for improving sleep, and the term "sleep improvement" as used herein is one of an increase in non-REM sleep time, an increase in sleep time per day, or a reduction in sleep onset latency. It points to the above.

ホエイタンパク質加水分解物(左)またはホエイタンパク質濃縮物(右)の投与後12時間のノンレム睡眠時間について、投与前日と投与日との比較を示す。A comparison between the day before administration and the day of administration is shown for the non-REM sleep time of 12 hours after administration of whey protein hydrolyzate (left) or whey protein concentrate (right). ホエイタンパク質加水分解物(左)またはホエイタンパク質濃縮物(右)の投与後12時間の覚醒時間について、投与前日と投与日との比較を示す。A comparison between the day before administration and the day of administration is shown for the awakening time of 12 hours after administration of whey protein hydrolyzate (left) or whey protein concentrate (right). ホエイタンパク質加水分解物(左)またはホエイタンパク質濃縮物(右)の投与後1時間のノンレム睡眠時間について、投与前日と投与日との比較を示す。A comparison between the day before administration and the day of administration is shown for the non-REM sleep time of 1 hour after administration of whey protein hydrolyzate (left) or whey protein concentrate (right).

(睡眠改善用組成物)
本願の睡眠改善用組成物について説明する。
本願の睡眠改善用組成物は、ホエイタンパク質を加水分解したものである。
より具体的には、
ホエイタンパク質加水分解物の分解率が25%以上であり、
分子量分布は10kDa以下、メインピーク200Da〜3kDaであり、
APL(平均ペプチド鎖長)は2〜8であり、
遊離アミノ酸含量が20%以下であり、
抗原性がβ-ラクトグロブリンの抗原性の1/10,000以下、
という特徴を有するものである。
本願の睡眠改善用組成物に使用するホエイタンパク質加水分解物には、全長のαラクトアルブミンは実質的に含まれていない(HPLCによる当該ホエイタンパク質加水分解物の分析結果に基づく。データを示さず。)。より具体的には、当該ホエイタンパク質加水分解物に含まれる全長のαラクトアルブミンの量は、加水分解前のホエイタンパク質に含まれるαラクトアルブミンの量の10%以下、好ましくは、5%以下、2%以下、1%以下、0.5%以下、0.2%以下、又は0.1%以下である。
睡眠改善用組成物のホエイタンパク質加水分解物の分解率は、遊離のアミノ基を修飾して測定するオルトフタルアルデヒド(OPA)法等で測定することができる。ホエイタンパク質加水分解物の分子量分布は、High performance size exclusion chromatography (HPSEC)法等の方法で測定することができる。APL(平均ペプチド鎖長)は、TNBS(2,4,6-トリニトロベンゼンスルホン酸)法等の方法によって測定することができる。遊離アミノ酸含量は、75%エタノール等で遊離アミノ酸を抽出して、アミノ酸分析装置等で測定することができる。抗原性はInhibition ELISA法により評価することができる。
(Sleep improvement composition)
The sleep improving composition of the present application will be described.
The sleep-improving composition of the present application is a hydrolyzed whey protein.
More specifically
The decomposition rate of whey protein hydrolyzate is 25% or more,
The molecular weight distribution is 10 kDa or less, the main peak is 200 Da to 3 kDa, and
APL (mean peptide chain length) is 2-8,
Free amino acid content is 20% or less
Antigenicity is 1 / 10,000 or less of the antigenicity of β-lactoglobulin,
It has the feature.
The whey protein hydrolyzate used in the sleep-improving composition of the present application does not substantially contain full-length α-lactalbumin (based on the analysis results of the whey protein hydrolyzate by HPLC. No data is shown. .). More specifically, the total amount of α-lactalbumin contained in the whey protein hydrolyzate is 10% or less, preferably 5% or less, of the amount of α-lactalbumin contained in the whey protein before hydrolysis. 2% or less, 1% or less, 0.5% or less, 0.2% or less, or 0.1% or less.
The decomposition rate of the whey protein hydrolyzate of the sleep improving composition can be measured by the orthophthalaldehyde (OPA) method or the like, which measures by modifying a free transamination group. The molecular weight distribution of whey protein hydrolyzate can be measured by a method such as High performance size exclusion chromatography (HPSEC) method. The APL (average peptide chain length) can be measured by a method such as the TNBS (2,4,6-trinitrobenzenesulfonic acid) method. The free amino acid content can be measured by extracting free amino acids with 75% ethanol or the like and using an amino acid analyzer or the like. Antigenicity can be evaluated by the inhibition ELISA method.

(睡眠改善用組成物の摂取量)
本発明の睡眠改善用組成物は、上記したように複数のペプチドを含むことから、2つ以上のペプチドの相加・相乗効果により0.01g/日以上の摂取で睡眠改善作用を発現しうる。一方、本発明の睡眠改善用組成物は、抗原性がβ-ラクトグロブリンの1/10,000以下で安全に摂取できるため、摂取量は投与対象者や食品の形態に応じて0.025g/日以上、0.1g/日以上、0.25g/日以上、1g/日以上、又は2.5g/日以上、及び、30g/日以下、20g/日以下、10g/日以下、5g/日以下、2.5g/日以下、又は1g/日以下とすることができる。
本発明の睡眠改善用組成物は、以下に記載のとおり、食品、食品組成物、医薬品、医薬品組成物、及び飼料に添加することができるが、その際の睡眠改善用組成物の添加量は上記した有効量が摂取できるよう適宜調整すればよい。
(Intake of sleep improving composition)
Since the composition for improving sleep of the present invention contains a plurality of peptides as described above, it is possible to exhibit a sleep improving effect at an intake of 0.01 g / day or more due to the additive / synergistic effect of two or more peptides. On the other hand, since the sleep-improving composition of the present invention can be safely ingested with an antigenicity of 1 / 10,000 or less of β-lactoglobulin, the intake amount is 0.025 g / day or more depending on the administration subject and the form of food. 0.1g / day or more, 0.25g / day or more, 1g / day or more, or 2.5g / day or more, and 30g / day or less, 20g / day or less, 10g / day or less, 5g / day or less, 2.5g / day It can be less than or equal to 1 g / day or less.
The sleep-improving composition of the present invention can be added to foods, food compositions, pharmaceuticals, pharmaceutical compositions, and feeds as described below, and the amount of the sleep-improving composition added at that time is It may be adjusted appropriately so that the above-mentioned effective amount can be ingested.

(睡眠改善用組成物の睡眠改善作用の評価方法)
本発明の睡眠改善用組成物の睡眠改善作用は、実施例に記載したラットを対象とした動物試験により確認することができる。
(Evaluation method of sleep improving effect of sleep improving composition)
The sleep-improving effect of the sleep-improving composition of the present invention can be confirmed by the animal test on rats described in Examples.

(睡眠改善用組成物の製造方法)
本発明の睡眠改善用組成物の有効成分であるホエイタンパク質加水分解物は、例えば特開平4-112753号公報で報告されている方法によって得ることができる。この方法では、ホエイタンパク質をpH6〜10、50〜70℃とし、これに耐熱性のタンパク質加水分解酵素を加えて熱変性させながら酵素分解し、これを加熱して酵素を失活させることによって得られる。なお、上記酵素分解を行う前に、ホエイタンパク質をpH6〜10、20〜55℃においてタンパク質加水分解酵素を用いて酵素分解し、これを冷却することなく直ちに上記条件で酵素分解すると収率を一層高めることができる。
(Manufacturing method of sleep improving composition)
The whey protein hydrolyzate, which is the active ingredient of the sleep improving composition of the present invention, can be obtained, for example, by the method reported in JP-A-4-112753. In this method, whey protein is adjusted to pH 6-10, 50-70 ° C, and heat-resistant protein hydrolase is added to it for enzymatic decomposition while heat denaturation, and this is heated to inactivate the enzyme. Be done. Before performing the above enzymatic decomposition, whey protein is enzymatically decomposed at pH 6 to 10 and 20 to 55 ° C. using a protein hydrolase, and the whey protein is immediately enzymatically decomposed under the above conditions without cooling to further increase the yield. Can be enhanced.

また、上記のように調製したホエイタンパク質加水分解物を、分画分子量1kDa〜20kDa、好ましくは、2kDa〜10kDaの限外濾過(UF)膜及び/又は分画分子量100Da〜500Da、好ましくは150Da〜300Daのナノ濾過(NF)膜から選ばれる方法で濃縮することも可能である。このような膜処理により、ホエイタンパク質加水分解物の平均分子量を300〜500Daとすることによって、さらに苦味を軽減し、透明性を向上させることが可能である。 Further, the whey protein hydrolyzate prepared as described above is subjected to an ultrafiltration (UF) membrane having a molecular weight cut off of 1 kDa to 20 kDa, preferably 2 kDa to 10 kDa, and / or a molecular weight cut off from 100 Da to 500 Da, preferably 150 Da to. It is also possible to concentrate by a method selected from 300 Da nanofiltration (NF) membranes. By such a membrane treatment, the average molecular weight of the whey protein hydrolyzate is set to 300 to 500 Da, so that the bitterness can be further reduced and the transparency can be improved.

本発明におけるホエイタンパク質は、ウシやヤギ、ヒツジ、ヒト等の哺乳類の乳から調製したホエイ、その凝集物、粉末、あるいは精製タンパク質をいい、これを酵素反応させる時は水溶液の状態で使用する。 The whey protein in the present invention refers to whey prepared from the milk of mammals such as cows, goats, sheep and humans, its aggregates, powders, or purified proteins, and is used in an aqueous state when it is enzymatically reacted.

特開平4-112753号公報で報告されている方法によってホエイタンパク質加水分解物を調製する場合、前述の溶液をpH6〜10に調整するが、通常ホエイタンパク質はこの範囲のpHになっているので格別pHの調整を行う必要はないが、必要な場合は、塩酸、クエン酸及び乳酸等の酸溶液あるいは苛性ソーダ、水酸化カルシウム及び燐酸ソーダ等のアルカリ溶液を用いてpH6〜10とする。加熱は50〜70℃で行うが、耐熱性のタンパク質加水分解酵素は、この温度で添加するよりも、むしろ加熱前から加え酵素分解を行った方が収率の面から好ましい。 When preparing a whey protein hydrochloride by the method reported in JP-A-4-112753, the pH of the above solution is adjusted to 6 to 10, but the pH of whey protein is usually in this range, so it is exceptional. It is not necessary to adjust the pH, but if necessary, use an acid solution such as hydrochloric acid, citric acid and lactic acid or an alkaline solution such as caustic soda, calcium hydroxide and sodium phosphate to adjust the pH to 6-10. Although heating is carried out at 50 to 70 ° C., it is preferable to add the thermostable protein hydrolase before heating and carry out enzymatic decomposition rather than adding it at this temperature in terms of yield.

また、一般的なプロテアーゼの至適温度は40℃以下であるが、耐熱性のタンパク質加水分解酵素の至適温度は45℃以上であり、耐熱性のタンパク質加水分解酵素としては、従来このような至適温度を有する耐熱性のタンパク質加水分解酵素として知られているものであれば特に制限なく使用できる。このような耐熱性のタンパク質加水分解酵素としては、パパイン、サーモリシン、サーモリシンS、プロテアーゼS(商品名)、プロレザー(商品名)、サモアーゼ(商品名)、アルカラーゼ(商品名)、プロチンA(商品名)等を例示することができる。耐熱性のタンパク質加水分解酵素は、80℃で30分加熱して残存活性が約10%あるいはそれ以上になるものが望ましい。また、単独よりも複数の酵素を併用する方が効果的である。反応は、30分〜10時間程度行うことが好ましい。
最後に、反応液を加熱して酵素を失活させる。酵素の失活は、反応液を100℃以上で10秒間以上加熱することにより行うことができる。
In addition, the optimum temperature of a general protease is 40 ° C. or lower, but the optimum temperature of a heat-resistant protein hydrolase is 45 ° C. or higher. Anything known as a heat-resistant protein hydrolase having an optimum temperature can be used without particular limitation. Examples of such heat-resistant protein hydrolases include papain, thermolysin, thermolysin S, protease S (trade name), proleather (trade name), samoase (trade name), alcalase (trade name), and protein A (trade name). Name) etc. can be exemplified. The thermostable protein hydrolase is preferably heated at 80 ° C. for 30 minutes to have a residual activity of about 10% or more. In addition, it is more effective to use a plurality of enzymes in combination than to use them alone. The reaction is preferably carried out for about 30 minutes to 10 hours.
Finally, the reaction solution is heated to inactivate the enzyme. The inactivation of the enzyme can be performed by heating the reaction solution at 100 ° C. or higher for 10 seconds or longer.

そして反応液を遠心分離して上清を回収し、上清を乾燥して粉末製品とする。なお、遠心分離した時に生ずる沈殿物は上清に比べ低アレルゲン化の程度が小さいので、これを除去した方が好ましいが、勿論反応液をそのまま乾燥して使用しても差し支えない。 Then, the reaction solution is centrifuged to collect the supernatant, and the supernatant is dried to obtain a powder product. Since the degree of allergenization of the precipitate formed during centrifugation is smaller than that of the supernatant, it is preferable to remove it, but of course, the reaction solution may be dried and used as it is.

本発明の睡眠改善用組成物はそのまま使用してもよいが、食品、医薬品、及び飼料に通常含まれる他の原材料とともに使用できることから、常法に従い、粉末剤、顆粒剤、錠剤、カプセル剤、ドリンク剤等に用いることも出来る。また、ヨーグルト、乳飲料、ウエハース等の飲食品、及び飼料に配合することも可能である。 The sleep-improving composition of the present invention may be used as it is, but since it can be used together with other raw materials usually contained in foods, pharmaceuticals, and feeds, powders, granules, tablets, capsules, according to a conventional method, It can also be used as a drink. It can also be added to foods and drinks such as yogurt, milk drinks and wafers, and feed.

以下に実施例、試験例を示し、本発明について詳細に説明するが、これらは単に例示するのみであり、本発明はこれらによって何ら限定されるものではない。 Examples and test examples are shown below, and the present invention will be described in detail, but these are merely examples, and the present invention is not limited thereto.

(実施例1)
ホエイタンパク質10%水溶液1Lに、パパイン50U/g・ホエイタンパク質及びプロレザー(天野エンザイム社製)150U/g・ホエイタンパク質を加え、pH8に調整し、55℃において6時間ホエイタンパク質を変性させながら酵素分解を行った。反応液を100℃で15秒間以上加熱して酵素を失活させ、遠心分離して上清を回収し、これを乾燥してホエイタンパク質加水分解物(実施例品1)を得た。
得られたホエイタンパク質加水分解物の分子量分布は10kDa以下、メインピークは1.3kDa、APLは7.2、すべての構成成分に対する遊離アミノ酸含量は18.9%であった。
Inhibition ELISA法によってβ-ラクトグロブリンに対する抗原性の低下を測定したところ1/10,000以下で、分解率は28%、収率(酵素反応液を遠心分離し、仕込み量の乾燥重量に対する上清の乾燥重量の比率(%))は80.3%であった。
このようにして得られたホエイタンパク質加水分解物は、そのまま本発明の睡眠改善用組成物として使用可能である。
(Example 1)
Papain 50U / g, whey protein and Proleather (manufactured by Amano Enzyme) 150U / g, whey protein are added to 1L of a 10% whey protein aqueous solution, adjusted to pH 8, and the enzyme is denatured at 55 ° C for 6 hours. It was disassembled. The reaction solution was heated at 100 ° C. for 15 seconds or longer to inactivate the enzyme, centrifuged to collect the supernatant, and dried to obtain a whey protein hydrolyzate (Example product 1).
The molecular weight distribution of the obtained whey protein hydrolyzate was 10 kDa or less, the main peak was 1.3 kDa, the APL was 7.2, and the free amino acid content for all the constituents was 18.9%.
The decrease in antigenicity to β-lactoglobulin was measured by the inhibition ELISA method and found to be 1 / 10,000 or less, the decomposition rate was 28%, and the yield (the enzyme reaction solution was centrifuged and the supernatant was dried based on the dry weight of the charged amount. The weight ratio (%)) was 80.3%.
The whey protein hydrolyzate thus obtained can be used as it is as the sleep improving composition of the present invention.

(試験例1)
ホエイタンパク質加水分解物を使用して、睡眠改善効果について評価した。
8週齢のWistar系雄性ラット(日本SLC社)を購入し、12時間ごとの明暗周期の下で、市販固形飼料CRF-1(オリエンタル酵母社製)を与えて、飼料と水を自由に摂取させた。ラットに、脳波及び筋電位を測定するための電極を装着する手術を実施し、回復期として1週間以上の期間をおいて、試験を実施した。
ホエイタンパク質分解物を水に溶解し、ラット体重1kgあたり2.5g経口投与した(FDAのガイドラインをもちいてヒトに換算すると、1日当たり約30gに相当する)、また、比較対象として、ホエイタンパク質濃縮物(タンパク質含量80%)を水に溶解し、ラット体重1kgあたり2.5g経口投与した。投与は17時〜18時(消灯1時間以内)に行い、投与前日の睡眠・覚醒時間と比較した。
脳波及び筋電位は睡眠解析ソフト「スリープサイン」(キッセイコムテック社製、Sleep sign ver2.0)を用いて、覚醒、ノンレム睡眠、レム睡眠の各睡眠ステージに分類した。
投与後12時間の覚醒時間、ノンレム睡眠時間を積算し、投与前日の覚醒時間、ノンレム睡眠時間と比較した。また、Student’s t-testの検定を行い、p<0.05で有意差ありと判定した。
(Test Example 1)
Whey protein hydrolyzate was used to evaluate sleep-improving effects.
Purchased an 8-week-old male Wistar rat (SLC Japan), fed a commercial solid feed CRF-1 (manufactured by Oriental Yeast Co., Ltd.) under a light-dark cycle every 12 hours, and freely ingested feed and water. I let you. Rats were operated on to attach electrodes for measuring brain waves and myoelectric potentials, and the test was conducted with a recovery period of 1 week or longer.
Whey protein degradation products were dissolved in water and orally administered at 2.5 g per 1 kg of rat body weight (corresponding to about 30 g per day when converted to humans using FDA guidelines), and whey protein concentrate for comparison. (Proteo content 80%) was dissolved in water and 2.5 g per 1 kg of rat body weight was orally administered. Administration was performed from 17:00 to 18:00 (within 1 hour after the lights were turned off), and compared with the sleep / wake time on the day before administration.
EEG and myoelectric potential were classified into sleep stages of arousal, non-REM sleep, and REM sleep using the sleep analysis software "Sleep sign" (Sleep sign ver2.0, manufactured by Kissei Comtech).
The awakening time and non-REM sleep time 12 hours after administration were integrated and compared with the awakening time and non-REM sleep time on the day before administration. In addition, Student's t-test test was performed, and it was judged that there was a significant difference when p <0.05.

図1、2に示すように、ホエイタンパク質加水分解物の投与により、投与後12時間のノンレム睡眠時間が、投与前日と比較して有意に増加し、覚醒時間が減少することが示された(投与前日を100%として表す。以下同じ。)。さらに、図3に示すように、ホエイタンパク質加水分解物の投与により、投与直後1時間の睡眠量が有意に増加していることから、睡眠導入作用があることが示唆された。ホエイタンパク質加水分解物には、全長のαラクトアルブミンは含まれていなかったので(HPLCによる当該ホエイタンパク質加水分解物の分析結果に基づく。データを示さず。)、観察された効果はαラクトアルブミンの効果ではない。
一方で、比較対象として用いたホエイタンパク質濃縮物では、投与12時間のノンレム睡眠時間、覚醒時間、及び投与直後1時間のノンレム睡眠時間は、投与前日と比較して差はなかった。
ホエイタンパク質の加水分解に、パパイン及びプロレザーとは異なるプロテアーゼ(システインエンドペプチダーゼ、メタロエンドペプチダーゼ、セリンエンドペプチダーゼ、アスパラギン酸プロテアーゼ)を使用した場合に、図1〜3と同様の結果が得られた(データを示さず)。
As shown in FIGS. 1 and 2, it was shown that the administration of whey protein hydrolyzate significantly increased the non-REM sleep time 12 hours after the administration and decreased the wakefulness time as compared with the day before the administration ( The day before administration is expressed as 100%. The same shall apply hereinafter). Furthermore, as shown in FIG. 3, the administration of whey protein hydrolyzate significantly increased the amount of sleep for 1 hour immediately after administration, suggesting that it has a sleep-inducing effect. Since the whey protein hydrolyzate did not contain full-length alpha-lactalbumin (based on the results of HPLC analysis of the whey protein hydrolyzate, no data shown), the observed effect was alpha-lactalbumin. Is not the effect of.
On the other hand, in the whey protein concentrate used as a comparison target, the non-REM sleep time of 12 hours after administration, the awakening time, and the non-REM sleep time of 1 hour immediately after administration were not different from those on the day before administration.
Similar results to FIGS. 1-3 were obtained when different proteases (cysteine endopeptidase, metalloendopeptidase, serine endopeptidase, aspartic protease) than papain and proleather were used to hydrolyze whey protein. (No data shown).

(実施例品2)睡眠改善用カプセル剤
表1に示す配合で原材料を混合後、常法により造粒し、カプセルに充填して、睡眠改善用カプセル剤を製造した。
(Example product 2) Capsules for sleep improvement After mixing the raw materials with the formulation shown in Table 1, granulated by a conventional method and filled into capsules to produce capsules for sleep improvement.

Figure 2020198791
Figure 2020198791

(実施例品3)睡眠改善用飲料
10gの実施例品1を700gの脱イオン水に添加し、50℃まで加熱後、9,500rpmで30分間撹拌混合した。
前記混合物に表2の原材料を添加した後、100mlのガラス瓶に充填し、95℃、15秒間殺菌後、密栓し、睡眠改善用飲料10本(100ml入り)を調製した。
(Example product 3) Beverage for improving sleep
10 g of Example Product 1 was added to 700 g of deionized water, heated to 50 ° C., and stirred and mixed at 9,500 rpm for 30 minutes.
After adding the raw materials shown in Table 2 to the mixture, the mixture was filled in a 100 ml glass bottle, sterilized at 95 ° C. for 15 seconds, and then sealed to prepare 10 sleep-improving beverages (containing 100 ml).

Figure 2020198791
Figure 2020198791

(実施例品4)イヌ用睡眠改善用飼料
5kgの実施例品1を95kgの脱イオン水に添加し、50℃まで加熱後、3,600rpmで40分間撹拌混合して、実施例品1を5kg/100kg含有する溶液を得た。この溶液20kgに、表3の原材料の全量を混合し、120℃、4分間殺菌して、本発明のイヌ用睡眠改善用飼料100kgを製造した。
(Example product 4) Feed for improving sleep for dogs
5 kg of Example Product 1 was added to 95 kg of deionized water, heated to 50 ° C., and then stirred and mixed at 3,600 rpm for 40 minutes to obtain a solution containing 5 kg / 100 kg of Example Product 1. The whole amount of the raw materials shown in Table 3 was mixed with 20 kg of this solution and sterilized at 120 ° C. for 4 minutes to prepare 100 kg of the feed for improving sleep for dogs of the present invention.

Figure 2020198791
Figure 2020198791

本発明は、新たな睡眠を改善する組成物として、ホエイタンパク質加水分解物を含む組成物と該組成物を含む食品、食品組成物、医薬品、医薬品組成物、及び飼料を提供するものである。本発明の組成物等を摂取することにより睡眠を改善できる。 The present invention provides a composition containing a whey protein hydrolyzate and a food containing the composition, a food composition, a pharmaceutical product, a pharmaceutical composition, and a feed as a new sleep-improving composition. Sleep can be improved by ingesting the composition of the present invention or the like.

Claims (7)

ホエイタンパク質加水分解物を有効成分とする睡眠改善用組成物。 A sleep-improving composition containing a whey protein hydrolyzate as an active ingredient. 前記睡眠改善用組成物が、ノンレム睡眠時間増加用組成物、睡眠時間増加用組成物、及び睡眠導入促進用組成物からなる群より選択される1つ以上であることを特徴とする、請求項1に記載の睡眠改善用組成物。 The claim is characterized in that the sleep improving composition is one or more selected from the group consisting of a non-REM sleep time increasing composition, a sleep time increasing composition, and a sleep induction promoting composition. The sleep improving composition according to 1. 前記ホエイタンパク質加水分解物の分解率が25%以上であることを特徴とする請求項1又は請求項2のいずれか1項に記載の睡眠改善用組成物。 The sleep-improving composition according to any one of claims 1 or 2, wherein the decomposition rate of the whey protein hydrolyzate is 25% or more. 前記ホエイタンパク質加水分解物が、以下の特徴を有するものである請求項1から請求項3のいずれか1項に記載の睡眠改善用組成物。
(A)分子量分布は10kDa以下、メインピーク200Da〜3kDaである。
(B)APL(平均ペプチド鎖長)は2〜8である。
(C)遊離アミノ酸含量が20%以下である。
(D)抗原性がβ-ラクトグロブリンの抗原性の1/10,000以下である。
The sleep-improving composition according to any one of claims 1 to 3, wherein the whey protein hydrolyzate has the following characteristics.
(A) The molecular weight distribution is 10 kDa or less, and the main peak is 200 Da to 3 kDa.
(B) APL (mean peptide chain length) is 2-8.
(C) The free amino acid content is 20% or less.
(D) The antigenicity is 1 / 10,000 or less of the antigenicity of β-lactoglobulin.
前記ホエイタンパク質加水分解物が、ホエイタンパク質をpH6〜10、50〜70℃において耐熱性のタンパク質加水分解酵素を用いて熱変性させながら酵素分解し、加熱して酵素を失活させて得られるものであることを特徴とする請求項1から請求項4のいずれか1項に記載の睡眠改善用組成物。 The whey protein hydrolyzate is obtained by enzymatically decomposing whey protein at pH 6-10 and 50-70 ° C using a heat-resistant protein hydrolase while thermally denaturing it, and heating to inactivate the enzyme. The sleep-improving composition according to any one of claims 1 to 4, wherein the composition is characterized by the above. 前記ホエイタンパク質加水分解物が、ホエイタンパク質をpH6〜10、20〜55℃においてタンパク質加水分解酵素を用いて酵素分解し、これを50〜70℃に昇温させ、pH6〜10、50〜70℃において耐熱性のタンパク質加水分解酵素を用いて未分解のホエイタンパク質を熱変性させながら酵素分解し、加熱して酵素を失活させて得られるものであることを特徴とする請求項1から請求項4のいずれか1項に記載の睡眠改善用組成物。 The whey protein hydrolyzate enzymatically decomposes whey protein at pH 6 to 10, 20 to 55 ° C. using a protein hydrolyzate enzyme, raises the temperature to 50 to 70 ° C., and pH 6 to 10, 50 to 70 ° C. The present invention is characterized in that it is obtained by enzymatically decomposing an undecomposed whey protein using a heat-resistant protein hydrolyzate while heat-denaturing it, and inactivating the enzyme by heating. The composition for improving sleep according to any one of 4. 請求項1から請求項6のいずれかに記載の睡眠改善用組成物を含むことを特徴とする睡眠改善用食品、睡眠改善用食品組成物、睡眠改善用医薬品、睡眠改善用医薬品組成物、又は睡眠改善用飼料。 A sleep-improving food, a sleep-improving food composition, a sleep-improving drug, a sleep-improving pharmaceutical composition, or a sleep-improving pharmaceutical composition, which comprises the sleep-improving composition according to any one of claims 1 to 6. Feed for improving sleep.
JP2019106129A 2019-06-06 2019-06-06 Compositions for improving sleep and foods, medicines, and feed containing the compositions Active JP7428480B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019106129A JP7428480B2 (en) 2019-06-06 2019-06-06 Compositions for improving sleep and foods, medicines, and feed containing the compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2019106129A JP7428480B2 (en) 2019-06-06 2019-06-06 Compositions for improving sleep and foods, medicines, and feed containing the compositions

Publications (2)

Publication Number Publication Date
JP2020198791A true JP2020198791A (en) 2020-12-17
JP7428480B2 JP7428480B2 (en) 2024-02-06

Family

ID=73741530

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019106129A Active JP7428480B2 (en) 2019-06-06 2019-06-06 Compositions for improving sleep and foods, medicines, and feed containing the compositions

Country Status (1)

Country Link
JP (1) JP7428480B2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022202985A1 (en) * 2021-03-24 2022-09-29 森永乳業株式会社 Peptide and composition containing peptide as active ingredient
WO2023054594A1 (en) * 2021-09-30 2023-04-06 雪印メグミルク株式会社 Method for producing peptide

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04112753A (en) * 1990-08-31 1992-04-14 Snow Brand Milk Prod Co Ltd Hydrolyzed whey protein having decreased allergen content and production thereof
WO2005094849A1 (en) * 2004-03-31 2005-10-13 Calpis Co., Ltd. Functional food for ameliorating engogenous melatonin secretion rhythm and functional food for ameliorating circadian rhythm
JP2011523547A (en) * 2008-04-29 2011-08-18 ディーエスエム アイピー アセッツ ビー.ブイ. Mixture of peptide-bound tryptophan and polypeptide-bound tryptophan
JP2012530779A (en) * 2009-06-22 2012-12-06 エスケー バイオファーマシューティカルズ カンパニー リミテッド Methods for treating or preventing fatigue
JP2018008916A (en) * 2016-07-15 2018-01-18 株式会社明治 Agent for promoting rise in amino acid concentrations in blood

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20012319A1 (en) 2001-11-06 2003-05-06 Mario Baraldi USE OF MILK SERUM CONTAINING SUBSTANCES IN BENZODIAZEPINO-SIMILE ACTIVITIES
CN1557475A (en) 2004-02-04 2004-12-29 高春平 Beautifying and fat reducing nutrients composition
CN1557196A (en) 2004-02-04 2004-12-29 高春平 Pressure regulating, sleep improving natural nutrients
CN108157963A (en) 2017-12-25 2018-06-15 广电计量检测(湖南)有限公司 Have effects that improve composition, tablet of sleep and preparation method thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04112753A (en) * 1990-08-31 1992-04-14 Snow Brand Milk Prod Co Ltd Hydrolyzed whey protein having decreased allergen content and production thereof
WO2005094849A1 (en) * 2004-03-31 2005-10-13 Calpis Co., Ltd. Functional food for ameliorating engogenous melatonin secretion rhythm and functional food for ameliorating circadian rhythm
JP2011523547A (en) * 2008-04-29 2011-08-18 ディーエスエム アイピー アセッツ ビー.ブイ. Mixture of peptide-bound tryptophan and polypeptide-bound tryptophan
JP2012530779A (en) * 2009-06-22 2012-12-06 エスケー バイオファーマシューティカルズ カンパニー リミテッド Methods for treating or preventing fatigue
JP2018008916A (en) * 2016-07-15 2018-01-18 株式会社明治 Agent for promoting rise in amino acid concentrations in blood

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022202985A1 (en) * 2021-03-24 2022-09-29 森永乳業株式会社 Peptide and composition containing peptide as active ingredient
WO2023054594A1 (en) * 2021-09-30 2023-04-06 雪印メグミルク株式会社 Method for producing peptide

Also Published As

Publication number Publication date
JP7428480B2 (en) 2024-02-06

Similar Documents

Publication Publication Date Title
JP5626807B2 (en) Mixture of peptide-bound tryptophan and polypeptide-bound tryptophan
US9993515B2 (en) Methods of treatment using water-soluble tryptophan-containing peptides obtained by the hydrolysis of hens eggs lysozyme
AU2009332369B2 (en) Muscle-building agent
AU2011221852B2 (en) Agent for preventing muscular atrophy
JP2009517464A (en) Use of protein hydrolysates that enhance the activity of glucagon-like peptide 1
JP7428480B2 (en) Compositions for improving sleep and foods, medicines, and feed containing the compositions
WO2018021471A1 (en) Food composition for improving brain function
JP2004536030A (en) Method for producing tryptophan-rich peptide
JP6041242B2 (en) Peptides containing tryptophan
WO2015166938A1 (en) Food additive for producing food for preventing cranial nerve disease and/or improving brain function
KR20130004284A (en) Protein synthesis promoter
JP2016149989A (en) Food additive composition for preventing or improving sleep disorder
JP7417228B2 (en) Preventive agents for egg allergy, etc. and food compositions containing the same
CN102573880A (en) Fat accumulation suppressor
WO2019151137A1 (en) Food composition to improve brain function

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220428

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230315

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230407

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231004

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240124

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240125

R150 Certificate of patent or registration of utility model

Ref document number: 7428480

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150